Hims & Hers Health, Inc., faces GLP-1 headwinds, volatility, and regulatory risk but has strong revenue growth and global ...
About Septerna Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR ...
18h
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
Tectonic Therapeutic, Inc. (NASDAQ: TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic ...
Novo Nordisk (NVO) shares fell over 15% on Monday after the company’s next-generation obesity drug CagriSema delivered less weight loss than Eli Lilly’s (LLY) competing treatment in a phase 3 trial, ...
Investor's Business Daily on MSN
Novo Nordisk dives as next-gen obesity drug fails to match Eli Lilly's Zepbound
Novo Nordisk stock dived after Novo's next-generation obesity drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. Lilly stock rose.
Peer-reviewed study characterizes in vitro and ex vivo activities of novel antibody agonists generated using Abalone ...
New Cell-Based Assay Supports Drug Discovery Targeting Appetite Regulation, Stress Biology, and Autonomic Function ...
Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap ...
Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results